<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8907828</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20554</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Psychopharmacol. (Oxford)</journal-id>
<journal-title-group>
<journal-title>Journal of psychopharmacology (Oxford, England)</journal-title>
</journal-title-group>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27539931</article-id>
<article-id pub-id-type="pmc">6036900</article-id>
<article-id pub-id-type="doi">10.1177/0269881116661075</article-id>
<article-id pub-id-type="manuscript">NIHMS976095</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Sensorimotor gating of the startle reflex: what we said 25 years ago,
what has happened since then, and what comes next</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Swerdlow</surname>
<given-names>Neal R</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Braff</surname>
<given-names>David L</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geyer</surname>
<given-names>Mark A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Psychiatry, University of California San Diego School
of Medicine, La Jolla, CA, USA</aff>
<aff id="A2">
<label>2</label>Research Service, VA San Diego Healthcare System, San Diego, CA,
USA</aff>
<author-notes>
<corresp id="FN1">Corresponding author: Neal R. Swerdlow, Department of Psychiatry,
UC San Diego School of Medicine, La Jolla, CA 92093-0804, USA.
<email>nswerdlow@ucsd.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Declaration of conflicting interests</bold>
</p>
<p>The authors declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: In the past
three years, Dr Swerdlow has received consulting compensation from Genco, Inc.,
and Dr Geyer has received consulting compensation from Lundbeck, Omeros, Otsuka
and Sunovion, and holds an equity interest in San Diego Instruments.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>8</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>30</volume>
<issue>11</issue>
<fpage>1072</fpage>
<lpage>1081</lpage>
<!--elocation-id from pubmed: 10.1177/0269881116661075-->
<permissions>
<license license-type="permissions-link">
<license-p>Reprints and permissions: <ext-link ext-link-type="uri" xlink:href="sagepub.co.uk/journalsPermissions.nav">sagepub.co.uk/journalsPermissions.nav</ext-link></license-p>
</license>
</permissions>
<related-article ext-link-type="pmid" id="ra1" related-article-type="commentary-article" xlink:href="22291349" xlink:type="simple"></related-article>
<abstract>
<p id="P1">Our 1992 paper, ‘The neural substrates of sensorimotor gating of
the startle reflex: a review of recent findings and their implications’,
reviewed a series of (then) new and preliminary findings from cross-species
studies of prepulse inhibition of the startle reflex, and commented on their
implications. At the time that the report was composed, PubMed listed about 40
citations for studies using the search term ‘prepulse
inhibition’. In the ensuing 25 years, the field has added about 2700
such reports, reflecting the substantial growth in interest in prepulse
inhibition and its utility across a number of different experimental
applications. The 30th anniversary of the <italic>Journal of
Psychopharmacology</italic> provides an opportunity to comment briefly on
what was described in that 1992 report, how the field has progressed in the
subsequent decades, and the paths forward for studies of prepulse inhibition and
its use as an operational measure of sensorimotor gating. Among these future
paths, we highlight the use of prepulse inhibition as: an endophenotype for
genomic studies, and a biomarker for healthy brain circuitry, which may predict
sensitivity to psychotherapeutics. Our 1992 report was highly speculative and
based on paper-thin empirical data, yet viewed in a certain light, it appears to
have contained a basic roadmap for a journey spanning the next 25 years of
prepulse inhibition research… and ‘what a long, strange trip
it’s been’.</p>
</abstract>
<kwd-group>
<kwd>Antipsychotic</kwd>
<kwd>dopamine</kwd>
<kwd>prepulse inhibition</kwd>
<kwd>schizophrenia</kwd>
<kwd>sensorimotor gating</kwd>
<kwd>startle reflex</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>